| P50 | author | Sébastien Guillaume | Q44152384 |
| | Pierre-Michel Llorca | Q83120424 |
| | Ludovic Samalin | Q83120815 |
| P2093 | author name string | Mocrane Abbar | |
| | Philippe Courtet | |
| | Sylvie Lancrenon | |
| P2860 | cites work | Clinicians' attitudes toward the use of long-acting injectable antipsychotics | Q87029125 |
| | The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary | Q28213792 |
| | Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis | Q28303010 |
| | The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements | Q33566124 |
| | Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases | Q33600247 |
| | Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials | Q34160338 |
| | Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology | Q34162475 |
| | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis | Q34213209 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects | Q34315836 |
| | Systematic meta-review of depot antipsychotic drugs for people with schizophrenia | Q34387845 |
| | The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients | Q34573809 |
| | The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. | Q34585605 |
| | Clinical practice recommendations for bipolar disorder | Q34606360 |
| | Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons | Q34620095 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 |
| | Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature | Q34989186 |
| | The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. | Q35593695 |
| | Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia | Q35855167 |
| | Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics | Q35873789 |
| | Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists | Q36054996 |
| | Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa | Q36587739 |
| | A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia | Q37327871 |
| | Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 |
| | Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials | Q37451403 |
| | The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. | Q37581138 |
| | Second-generation antipsychotic long-acting injections: systematic review | Q37625686 |
| | Clinical guideline recommendations for antipsychotic long-acting injections | Q37625696 |
| | Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines | Q37790910 |
| | International consensus group on depression prevention in bipolar disorder | Q37954855 |
| | Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms | Q37966430 |
| | Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians? | Q38059983 |
| | What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? | Q38116564 |
| | Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). | Q39680993 |
| | The expert consensus guideline series. Treatment of behavioral emergencies 2005. | Q40368586 |
| | Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies | Q42610208 |
| | Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment | Q43238492 |
| | Antipsychotic long-acting injections: prescribing practice in the UK. | Q43251056 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 |
| | Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia | Q44673143 |
| | Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics | Q44742715 |
| | Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection | Q46317070 |
| | Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting | Q46621896 |
| | Clinical practice guidelines. Treatment of schizophrenia. | Q48622464 |
| | Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample | Q49157018 |
| | Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. | Q51872425 |
| | Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. | Q53853216 |
| | Dépistage et prise en charge du trouble bipolaire : Méthodologie | Q57834724 |
| | Dépistage et prise en charge du trouble bipolaire : Résultats | Q57834728 |
| | Guidelines for depot antipsychotic treatment in schizophrenia | Q58231296 |
| | Attitudes of psychiatrists toward antipsychotic depot medication | Q79459271 |
| | Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis | Q79695680 |
| | How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? | Q82786966 |
| | [Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec] | Q84559194 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 340 | |
| P577 | publication date | 2013-12-20 | |
| P1433 | published in | BMC Psychiatry | Q15750257 |
| P1476 | title | Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness | |
| P478 | volume | 13 | |